Cargando…
Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
Recently, ketamine has been demonstrated to exert rapid-acting antidepressant effects in patients with depression, including those with treatment-resistant depression, and this discovery has been regarded as the most significant advance in drug development for the treatment of depression in over 50...
Autores principales: | Chaki, Shigeyuki, Fukumoto, Kenichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588184/ https://www.ncbi.nlm.nih.gov/pubmed/26393618 http://dx.doi.org/10.3390/ph8030590 |
Ejemplares similares
-
Targeting of Metabotropic Glutamate Receptors for the Development of
Novel Antidepressants
por: Chaki, Shigeyuki, et al.
Publicado: (2019) -
Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine
por: Chaki, Shigeyuki, et al.
Publicado: (2019) -
Vasopressin V(1B) Receptor Antagonists as Potential Antidepressants
por: Chaki, Shigeyuki
Publicado: (2021) -
Metabotropic Glutamate Receptors: Potential Drug Targets for Psychiatric Disorders
por: Yasuhara, Akito, et al.
Publicado: (2010) -
Role of 5-HT(1A) Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine
por: Fukumoto, Kenichi, et al.
Publicado: (2017)